Evidence map›Paper›PMID 32256641›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2020

Mechanisms of Berberine for the Treatment of Atherosclerosis Based on Network Pharmacology.

Xuejiao Xie, Xingyu Ma, Siyu Zeng, Wansi Tang, Liucheng Xiao, Chenggong Zhu, Rong Yu

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Effects of Berberine on Atherosclerosis.Frontiers in pharmacology · 2021
    Review
  8. Molecular Targets and Mechanisms ofEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
  9. Ferroptosis: New Dawn for Overcoming the Cardio-Cerebrovascular Diseases.Frontiers in cell and developmental biology · 2021
    Review
  10. Article
  11. Avicenna journal of phytomedicine
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xuejiao XieDepartment of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID https://orcid.org/0000-0001-7420-9681
Xingyu MaDepartment of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.
Siyu ZengDepartment of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.
Wansi TangDepartment of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.
Liucheng XiaoDepartment of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID https://orcid.org/0000-0003-4154-439X
Chenggong ZhuDepartment of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.
Rong YuCollege of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID https://orcid.org/0000-0002-7950-218X
Hunan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis is a common metabolic disease characterized by lipid metabolic disorder. The processes of atherosclerosis include endothelial dysfunction, new endothelial layer formation, lipid sediment, foam cell formation, plaque formation, and plaque burst. Owing to the adverse effects of first-line medications, it is urgent to discover new medications to deal with atherosclerosis. Berberine is one of the most promising natural products derived from traditional Chinese medicine. However, the panoramic mechanism of berberine against atherosclerosis has not been discovered clearly. In this study, we used network pharmacology to investigate the interaction between berberine and atherosclerosis. We identified potential targets related to berberine and atherosclerosis from several databases. A total of 31 and 331 putative targets for berberine and atherosclerosis were identified, respectively. Then, we constructed berberine and atherosclerosis targets with PPI data. Berberine targets network with PPI data had 3204 nodes and 79437 edges. Atherosclerosis targets network with PPI data had 5451 nodes and 130891 edges. Furthermore, we merged the two PPI networks and obtained the core PPI network from the merged PPI network. The core PPI network had 132 nodes and 3339 edges. At last, we performed functional enrichment analyses including GO and KEGG pathway analysis in David database. GO analysis indicated that the biological processes were correlated with G1/S transition of mitotic cells cycle. KEGG pathway analysis found that the pathways directly associated with berberine against atherosclerosis were cell cycle, ubiquitin mediated proteolysis, MAPK signaling pathway, and PI3K-Akt signaling pathway. After combining the results in context with the available treatments for atherosclerosis, we considered that berberine inhibited inflammation and cell proliferation in the treatment of atherosclerosis. Our study provided a valid theoretical foundation for future research.

Identifiers

PMID32256641
PMCPMC7106879
OpenAlexW3011102399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.